The DNA demethylating agent decitabine activates the TRAIL pathway and induces apoptosis in acute myeloid leukemia

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1832, Issue 1, 2013, Pages 114-120

  Soncini, Matías ^a,d   Santoro, Fabio ^a   Gutierrez, Arantxa ^b   Frigè, Gianmaria ^a   Romanenghi, Mauro ^a   Botrugno, Oronza A ^a   Pallavicini, Isabella ^a   Pelicci, PierGiuseppe ^a,c   Di Croce, Luciano ^b   Minucci, Saverio ^a,c  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b CENTRE FOR GENOMIC REGULATION CRG   (Spain)

^c UNIVERSITY OF MILAN   (Italy)

^d SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Acute myeloid leukemia; Apoptosis; Decitabine; DNA methylation; PML RAR; TRAIL

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CASPASE 8; CASPASE 9; LUCIFERASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CPG ISLAND; DEMETHYLATION; DNA METHYLATION; DNA MODIFICATION; DOSE RESPONSE; EPIGENETICS; GENE SILENCING; HISTONE ACETYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; REGULATORY MECHANISM; REGULATORY SEQUENCE; UPREGULATION;

APOPTOSIS; AZACITIDINE; CELL LINE, TUMOR; DNA METHYLATION; HISTONE DEACETYLASE INHIBITORS; HUMANS; LEUKEMIA, MYELOID, ACUTE; PROMOTER REGIONS, GENETIC; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84868593424     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2012.10.001     Document Type: Article

References (43)

1. Goldberg A.D., Allis C.D., Bernstein E. Epigenetics: a landscape takes shape. Cell 2007, 128:635-638.
2. Allis C., Jenuwein T., Reinberg D. Epigenetics 2007.
3. Dobosy J.R., Selker E.U. Emerging connections between DNA methylation and histone acetylation. Cell. Mol. Life Sci. 2001, 58:721-727.
4. Miller C.A., Campbell S.L., Sweatt J.D. DNA methylation and histone acetylation work in concert to regulate memory formation and synaptic plasticity. Neurobiol. Learn. Mem. 2008, 89:599-603.
5. Soppe W.J., Jasencakova Z., Houben A., Kakutani T., Meister A., Huang M.S., Jacobsen S.E., Schubert I., Fransz P.F. DNA methylation controls histone H3 lysine 9 methylation and heterochromatin assembly in Arabidopsis. EMBO J. 2002, 21:6549-6559.
6. Sharma S., Kelly T.K., Jones P.A. Epigenetics in cancer. Carcinogenesis 2010, 31:27-36.
7. Berdasco M., Esteller M. Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev. Cell 2010, 19:698-711.
8. Jones P.A., Baylin S.B. The epigenomics of cancer. Cell 2007, 128:683-692.
9. de The H., Chen Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat. Rev. Cancer 2010, 10:775-783.
10. Di Croce L., Raker V.A., Corsaro M., Fazi F., Fanelli M., Faretta M., Fuks F., Lo Coco F., Kouzarides T., Nervi C., Minucci S., Pelicci P.G. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 2002, 295:1079-1082.
11. Martens J.H., Brinkman A.B., Simmer F., Francoijs K.J., Nebbioso A., Ferrara F., Altucci L., Stunnenberg H.G. PML-RARalpha/RXR alters the epigenetic landscape in acute promyelocytic leukemia. Cancer Cell 2010, 17:173-185.
12. Villa R., De Santis F., Gutierrez A., Minucci S., Pelicci P.G., Di Croce L. Epigenetic gene silencing in acute promyelocytic leukemia. Biochem. Pharmacol. 2004, 68:1247-1254.
13. Claus R., Almstedt M., Lubbert M. Epigenetic treatment of hematopoietic malignancies: in vivo targets of demethylating agents. Semin. Oncol. 2005, 32:511-520.
14. Garcia-Manero G., Kantarjian H.M., Sanchez-Gonzalez B., Yang H., Rosner G., Verstovsek S., Rytting M., Wierda W.G., Ravandi F., Koller C., Xiao L., Faderl S., Estrov Z., Cortes J., O'Brien S., Estey E., Bueso-Ramos C., Fiorentino J., Jabbour E., Issa J.P. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood 2006, 108:3271-3279.
15. Insinga A., Monestiroli S., Ronzoni S., Gelmetti V., Marchesi F., Viale A., Altucci L., Nervi C., Minucci S., Pelicci P.G. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat. Med. 2005, 11:71-76.
16. Minucci S., Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 2006, 6:38-51.
17. Momparler R.L. Epigenetic therapy of cancer with 5-aza-2'-deoxycytidine (decitabine). Semin. Oncol. 2005, 32:443-451.
18. Villar-Garea A., Esteller M. Histone deacetylase inhibitors: understanding a new wave of anticancer agents. Int. J. Cancer 2004, 112:171-178.
19. Santi D.V., Norment A., Garrett C.E. Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc. Natl. Acad. Sci. U. S. A. 1984, 81:6993-6997.
20. Kantarjian H.M., Issa J.P. Decitabine dosing schedules. Semin. Hematol. 2005, 42:S17-S22.
21. Kozar K., Kaminski R., Switaj T., Oldak T., Machaj E., Wysocki P.J., Mackiewicz A., Lasek W., Jakobisiak M., Golab J. Interleukin 12-based immunotherapy improves the antitumor effectiveness of a low-dose 5-Aza-2'-deoxycitidine treatment in L1210 leukemia and B16F10 melanoma models in mice. Clin. Cancer Res. 2003, 9:3124-3133.
22. Tsai H.C., Li H., Van Neste L., Cai Y., Robert C., Rassool F.V., Shin J.J., Harbom K.M., Beaty R., Pappou E., Harris J., Yen R.W., Ahuja N., Brock M.V., Stearns V., Feller-Kopman D., Yarmus L.B., Lin Y.C., Welm A.L., Issa J.P., Minn I., Matsui W., Jang Y.Y., Sharkis S.J., Baylin S.B., Zahnow C.A. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 2012, 21:430-446.
23. Cameron E.E., Bachman K.E., Myohanen S., Herman J.G., Baylin S.B. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 1999, 21:103-107.
24. Soriano A.O., Yang H., Faderl S., Estrov Z., Giles F., Ravandi F., Cortes J., Wierda W.G., Ouzounian S., Quezada A., Pierce S., Estey E.H., Issa J.P., Kantarjian H.M., Garcia-Manero G. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007, 110:2302-2308.
25. Altucci L., Minucci S. Epigenetic therapies in haematological malignancies: searching for true targets. Eur. J. Cancer 2009, 45:1137-1145.
26. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:9821-9826.
27. Villa R., Pasini D., Gutierrez A., Morey L., Occhionorelli M., Vire E., Nomdedeu J.F., Jenuwein T., Pelicci P.G., Minucci S., Fuks F., Helin K., Di Croce L. Role of the polycomb repressive complex 2 in acute promyelocytic leukemia. Cancer Cell 2007, 11:513-525.
28. Hendzel M.J., Nishioka W.K., Raymond Y., Allis C.D., Bazett-Jones D.P., Th'ng J.P. Chromatin condensation is not associated with apoptosis. J. Biol. Chem. 1998, 273:24470-24478.
29. Gargiulo G., Levy S., Bucci G., Romanenghi M., Fornasari L., Beeson K.Y., Goldberg S.M., Cesaroni M., Ballarini M., Santoro F., Bezman N., Frige G., Gregory P.D., Holmes M.C., Strausberg R.L., Pelicci P.G., Urnov F.D., Minucci S. NA-Seq: a discovery tool for the analysis of chromatin structure and dynamics during differentiation. Dev. Cell 2009, 16:466-481.
30. McArthur M., Gerum S., Stamatoyannopoulos G. Quantification of DNaseI-sensitivity by real-time PCR: quantitative analysis of DNaseI-hypersensitivity of the mouse beta-globin LCR. J. Mol. Biol. 2001, 313:27-34.
31. Lanotte M., Martin-Thouvenin V., Najman S., Balerini P., Valensi F., Berger R. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 1991, 77:1080-1086.
32. Kramer O.H., Muller S., Buchwald M., Reichardt S., Heinzel T. Mechanism for ubiquitylation of the leukemia fusion proteins AML1-ETO and PML-RARalpha. FASEB J. 2008, 22:1369-1379.
33. Minucci S., Monestiroli S., Giavara S., Ronzoni S., Marchesi F., Insinga A., Diverio D., Gasparini P., Capillo M., Colombo E., Matteucci C., Contegno F., Lo-Coco F., Scanziani E., Gobbi A., Pelicci P.G. PML-RAR induces promyelocytic leukemias with high efficiency following retroviral gene transfer into purified murine hematopoietic progenitors. Blood 2002, 100:2989-2995.
34. Bodmer J.L., Holler N., Reynard S., Vinciguerra P., Schneider P., Juo P., Blenis J., Tschopp J. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat. Cell Biol. 2000, 2:241-243.
35. Johnson C.R., Jarvis W.D. Caspase-9 regulation: an update. Apoptosis 2004, 9:423-427.
36. Kischkel F.C., Lawrence D.A., Chuntharapai A., Schow P., Kim K.J., Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000, 12:611-620.
37. Sprick M.R., Weigand M.A., Rieser E., Rauch C.T., Juo P., Blenis J., Krammer P.H., Walczak H. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 2000, 12:599-609.
38. Nebbioso A., Clarke N., Voltz E., Germain E., Ambrosino C., Bontempo P., Alvarez R., Schiavone E.M., Ferrara F., Bresciani F., Weisz A., de Lera A.R., Gronemeyer H., Altucci L. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat. Med. 2005, 11:77-84.
39. Xu J., Zhou J.Y., Wei W.Z., Philipsen S., Wu G.S. Sp1-mediated TRAIL induction in chemosensitization. Cancer Res. 2008, 68:6718-6726.
40. Villa R., Morey L., Raker V.A., Buschbeck M., Gutierrez A., De Santis F., Corsaro M., Varas F., Bossi D., Minucci S., Pelicci P.G., Di Croce L. The methyl-CpG binding protein MBD1 is required for PML-RARalpha function. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:1400-1405.
41. Ferguson A.T., Lapidus R.G., Davidson N.E. Demethylation of the progesterone receptor CpG island is not required for progesterone receptor gene expression. Oncogene 1998, 17:577-583.
42. Altucci L., Rossin A., Raffelsberger W., Reitmair A., Chomienne C., Gronemeyer H. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat. Med. 2001, 7:680-686.
43. Lund P., Kotova I., Kedinger V., Khanwalkar H., Voltz E., Hahn W.C., Gronemeyer H. Transformation-dependent silencing of tumor-selective apoptosis-inducing TRAIL by DNA hypermethylation is antagonized by decitabine. Mol. Cancer Ther. 2011, 10:1611-1623.